Canis Lupus Familiaris Hair

Dosage for Canis Lupus Familiaris Hair must be highly individualized based on the patient's sensitivity level. There is no 'standard' dose for all patients.

Diagnostic Testing

• Skin Prick Test (SPT): Usually, a drop of the 1:10 or 1:20 w/v glycerinated extract is applied to the skin, followed by a prick with a sterile lancet. Results are read after 15 to 20 minutes.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a 1:100 to 1:1000 dilution of the aqueous extract may be injected intradermally (0.02 mL) to create a small bleb.

Immunotherapy (SCIT)

• Build-up Phase: Treatment begins with a very low dose (e.g., 0.05 mL of a 1:100,000 dilution). Injections are typically given 1–2 times per week, with the dose increasing by 25–50% each time, provided the patient tolerates the previous dose.
• Maintenance Phase: Once the 'top dose' or 'maintenance dose' is reached (often 0.5 mL of a 1:100 or 1:20 concentration), the interval between injections is increased to every 2–4 weeks. Maintenance therapy usually continues for 3 to 5 years.

Canis Lupus Familiaris Hair extracts are generally approved for use in children. Pediatric dosing follows the same escalation logic as adult dosing, though clinicians may exercise more caution with the rate of increase in very young children (typically those over age 5). Immunotherapy is rarely initiated in children under the age of 5 due to the difficulty of monitoring for systemic reactions and the child's inability to communicate early symptoms of anaphylaxis.

Renal Impairment

No specific dosage adjustments are provided for renal impairment, as the systemic load of the protein extract is extremely low. However, clinicians should monitor for any delayed clearance of inflammatory mediators if a reaction occurs.

Hepatic Impairment

No adjustments are typically required for hepatic impairment. The primary concern in patients with liver disease would be the management of systemic reactions rather than the metabolism of the extract itself.

Elderly Patients

Elderly patients (over age 65) require careful evaluation. While the dose remains the same, the risk-to-benefit ratio may shift if the patient has significant cardiovascular disease, as they may be less able to tolerate a systemic reaction or the administration of epinephrine.

• Administration: These extracts must ONLY be administered by a healthcare professional trained in the management of anaphylaxis. They are given as a subcutaneous injection, usually in the posterior aspect of the upper arm.
• Observation: Patients MUST remain in the medical office for at least 30 minutes following every injection. Most fatal reactions occur within this window.
• Storage: Extracts must be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Freezing must be avoided as it can denature the allergenic proteins.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on the length of the delay. If the delay is more than 4 weeks during maintenance, the dose is usually reduced by one or two steps to ensure safety.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. Signs include intense local swelling, generalized hives, wheezing, or a drop in blood pressure. Treatment involves the immediate administration of intramuscular epinephrine and supportive care.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Never attempt to self-administer allergenic extracts.

Local reactions are the most frequent side effect of Canis Lupus Familiaris Hair administration. These occur at the site of the injection and include:

• Erythema (Redness): A red patch around the injection site, usually appearing within minutes to hours.
• Induration (Swelling): A firm, raised area at the site. If the swelling is larger than the size of a half-dollar (approx. 3 cm), it is considered a 'large local reaction.'
• Pruritus (Itching): Intense itching at the injection site is common and can be managed with topical cold packs or oral antihistamines.

These reactions typically resolve within 24 to 48 hours and are generally considered a normal part of the immune response to the extract.

Systemic reactions that are not life-threatening may occur, including:

• Generalized Urticaria (Hives): Itchy bumps appearing on parts of the body away from the injection site.
• Rhinitis: Sneezing, runny nose, or nasal congestion shortly after the injection.
• Conjunctivitis: Red, itchy, or watery eyes.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy session.

• Laryngeal Edema: Swelling of the throat, which can lead to difficulty swallowing or speaking.
• Bronchospasm: Tightening of the airways, resulting in wheezing and shortness of breath.
• Hypotension: A significant drop in blood pressure, which may cause dizziness or fainting.

> Warning: Stop taking Canis Lupus Familiaris Hair and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis:

• Difficulty Breathing: Wheezing, chest tightness, or a feeling of 'air hunger.'
• Swelling of the Face or Tongue: Angioedema can obstruct the airway.
• Rapid or Weak Pulse: Indicative of cardiovascular involvement.
• Nausea and Vomiting: Often an early sign of a systemic allergic reaction.
• Uterine Cramping: In female patients, systemic reactions can manifest as pelvic pain.
• Sense of Impending Doom: A psychological symptom often preceding severe physical collapse in anaphylaxis.

Long-term use of Canis Lupus Familiaris Hair in immunotherapy is generally well-tolerated. There is no evidence that long-term use causes autoimmune disease or chronic organ damage. The primary 'long-term' effect is the desired desensitization to dog allergens. However, some patients may develop a persistent sensitivity at the injection site (granuloma) if the extract contains aluminum-based adjuvants.

Most allergenic extracts, including Canis Lupus Familiaris Hair, carry a prominent warning regarding the risk of severe systemic reactions.

Summary of Warning: This product can cause severe, life-threatening systemic reactions, including anaphylaxis. It must only be administered in a setting where emergency equipment and trained personnel are available to treat such reactions. Patients with unstable or severe asthma are at a higher risk for fatal outcomes. Patients must be observed for at least 30 minutes post-injection.

Report any unusual symptoms to your healthcare provider immediately, even if they seem minor at first.

Before starting treatment with Canis Lupus Familiaris Hair, patients must undergo a thorough cardiovascular and respiratory assessment. Because the primary risk of this medication is anaphylaxis, anything that complicates the treatment of anaphylaxis is a major safety concern. Patients must be capable of understanding the risks and must be compliant with the required observation periods.

No FDA black box warnings are unique to 'Canis Lupus Familiaris Hair' specifically, but the entire class of Non-Standardized Allergenic Extracts carries a class-wide warning regarding Anaphylaxis Risk. The warning emphasizes that the extract should only be used by physicians experienced in providing safe immunotherapy and that the facility must be equipped with oxygen, epinephrine, and airway management tools.

• Allergic Reactions / Anaphylaxis Risk: This is the primary precaution. The risk is highest during the build-up phase and when switching to a new vial of extract, even if it is the same concentration, due to potential variations in non-standardized potency.
• Asthma Status: Patients with uncontrolled asthma should not receive immunotherapy injections. An asthma flare-up significantly increases the risk that a systemic reaction to the extract will become fatal.
• Cardiovascular Disease: Patients with significant heart disease may not tolerate the stress of a systemic reaction or the effects of the epinephrine required to treat it.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) are at increased risk because these drugs can block the life-saving effects of epinephrine.

• Pre-Injection Check: The clinician must check the patient's current health status, including whether they have had an asthma flare or a fever since the last dose.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before the injection to ensure lung function is stable.
• 30-Minute Wait: Strict adherence to the post-injection observation period is mandatory.
• Site Inspection: The injection site must be checked for local reactions before the patient leaves the clinic.

While the extract itself does not cause sedation, a systemic reaction or the administration of antihistamines/epinephrine to treat a reaction can impair the ability to drive or operate machinery. Patients should ensure they feel completely normal before leaving the clinic.

Alcohol consumption should be avoided for several hours after an injection. Alcohol can cause vasodilation, which may increase the rate of allergen absorption from the injection site and potentially trigger a delayed systemic reaction.

If a patient experiences a severe systemic reaction, the healthcare provider will re-evaluate the necessity of the treatment. In some cases, the dose will be significantly reduced; in others, treatment will be discontinued entirely. There is no 'withdrawal syndrome' associated with stopping allergenic extracts.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Canis Lupus Familiaris Hair.

• Beta-Adrenergic Blockers (Beta-Blockers): These medications (e.g., atenolol, carvedilol) are generally contraindicated in patients receiving allergenic immunotherapy. In the event of anaphylaxis, beta-blockers prevent epinephrine from working effectively on the heart and lungs, making the reaction much harder to reverse and potentially fatal.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (e.g., lisinopril, enalapril) may be at a higher risk for more severe systemic reactions to allergenic extracts.
• Tricyclic Antidepressants (TCAs): Medications like amitriptyline can potentiate the effects of epinephrine, leading to dangerous increases in blood pressure or heart rate if epinephrine is needed to treat a reaction.
• Monoamine Oxidase Inhibitors (MAOIs): Similar to TCAs, MAOIs can interfere with the breakdown of epinephrine, increasing the risk of a hypertensive crisis during emergency treatment.

• Antihistamines: While not dangerous, antihistamines (e.g., cetirizine, loratadine) can mask the early signs of a systemic reaction or suppress the results of diagnostic skin testing. Patients are typically asked to stop antihistamines 3–7 days before skin testing.
• Topical Corticosteroids: These can suppress skin reactivity if applied directly to the testing site, leading to false-negative results.

There are no direct food interactions with Canis Lupus Familiaris Hair. However, patients are advised to avoid heavy meals and vigorous exercise for 2 hours before and after an injection. Exercise increases blood flow and body temperature, which can accelerate the systemic absorption of the allergen.

• St. John's Wort: May theoretically interact with medications used to treat anaphylaxis.
• Feverfew/Ginkgo: Due to potential effects on platelet function and vasodilation, patients should inform their allergist if they are taking these supplements.

Canis Lupus Familiaris Hair does not typically interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: As it is the agent used for the test.
• Serum IgE Tests: Immunotherapy may lead to a transient increase in dog-specific IgE followed by a long-term decrease.
• IgG4 Levels: Successful immunotherapy will result in a measurable increase in dog-specific IgG4 antibodies.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'heart' or 'blood pressure' pills.

Canis Lupus Familiaris Hair must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with a forced expiratory volume in 1 second (FEV1) consistently below 70% of predicted values are at an unacceptable risk for fatal bronchospasm during a reaction.
• Recent Myocardial Infarction: Patients who have had a heart attack within the last 3–6 months should not start immunotherapy due to the risk of cardiac stress during anaphylaxis.
• History of Near-Fatal Anaphylaxis: If a patient has previously had a life-threatening reaction to a very small amount of dog allergen, the risks of SCIT may outweigh the benefits.
• Acute Infection: Injections should be withheld if the patient has a fever or an active respiratory infection, as this can lower the threshold for a systemic reaction.

• Autoimmune Disorders: Patients with active systemic lupus erythematosus or rheumatoid arthritis may experience a flare of their condition, though this is debated in clinical literature.
• Malignancy: Patients undergoing active chemotherapy or with unstable cancers are usually not candidates for immunotherapy.
• Pregnancy (Initiation): While maintenance doses can often be continued, immunotherapy should never be started during pregnancy due to the risk of anaphylaxis causing fetal hypoxia.

Patients allergic to dogs may also show sensitivity to other members of the Canidae family (e.g., wolves, foxes) due to the high conservation of the Can f 1 protein. There is also a known cross-reactivity between dog albumin (Can f 3) and the albumin of other mammals, such as cats, horses, and cows. This is known as the 'pork-cat' or 'animal-albumin' syndrome.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of asthma or heart disease, before prescribing Canis Lupus Familiaris Hair.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Canis Lupus Familiaris Hair in pregnant women. Animal reproduction studies have not been conducted. The primary risk during pregnancy is not the extract itself, but the potential for maternal anaphylaxis, which can lead to uterine contractions, placental abruption, and fetal hypoxia (lack of oxygen to the baby).

• Initiation: Immunotherapy should not be started during pregnancy.
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment may be continued at the same dose or a slightly reduced dose, as the risk of anaphylaxis is lower during the maintenance phase.

It is not known whether the allergenic proteins or the antibodies produced during immunotherapy are excreted in human milk. However, since the allergens are proteins that would be digested in the infant's stomach, the risk to the nursing infant is considered negligible. Breastfeeding is generally not a contraindication for receiving dog hair allergenic extract.

As previously noted, Canis Lupus Familiaris Hair is safe and effective for use in children, typically those aged 5 and older. It is particularly beneficial in children as it may prevent the 'allergic march'—the progression from allergic rhinitis to asthma. Clinicians must ensure the child is old enough to cooperate with the injection and the observation period.

Clinical studies of allergenic extracts often do not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In geriatric patients, the decision to use Canis Lupus Familiaris Hair must consider the presence of co-morbidities like coronary artery disease or COPD, which increase the danger of systemic reactions.

There are no specific guidelines for renal impairment. Because the dose is minute and administered subcutaneously, the kidneys are not significantly burdened. However, if a patient is on dialysis, the timing of the injection should be discussed with the nephrologist.

No dosage adjustment is required for patients with liver disease. The primary consideration is the patient's overall health and their ability to tolerate emergency medications like epinephrine if a reaction occurs.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant, planning to become pregnant, or nursing.

Canis Lupus Familiaris Hair extract functions as an immunomodulator. The primary allergens in the extract are proteins, most notably Can f 1 (a lipocalin) and Can f 2.

1. 1Diagnostic Phase: The extract introduces these proteins to skin-bound IgE. Cross-linking of IgE on mast cells leads to the release of histamine, leukotrienes, and prostaglandins, creating the wheal-and-flare response.
2. 2Therapeutic Phase: Repeated exposure via SCIT induces 'High-zone tolerance.' It promotes the expansion of CD4+ CD25+ Foxp3+ regulatory T-cells. These cells secrete IL-10, which suppresses the Th2 response and induces B-cells to switch production from IgE to IgG4. IgG4 acts as a 'blocking antibody,' preventing the allergen from reaching the IgE on mast cells.

The pharmacodynamic effect is measured by the change in the 'threshold dose' required to elicit an allergic response. Over time, the patient's skin test reactivity decreases, and their 'provocation threshold' (the amount of dog allergen they can inhale or touch before reacting) increases. The onset of this effect is slow, usually requiring 3–6 months of build-up therapy.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous absorption) |

| Protein Binding | N/A (Degraded by proteases) |

| Half-life | Immunological effect lasts years |

| Tmax | 15-30 minutes (for local reaction) |

| Metabolism | Local proteolytic degradation |

| Excretion | Renal (as peptide fragments) |

• Composition: A complex mixture of proteins, including Can f 1 through Can f 6.
• Molecular Weight: Varies by protein (e.g., Can f 1 is ~25 kDa).
• Solubility: Soluble in aqueous buffers and 50% glycerin.
• Source: Extracted from the hair and dander of Canis lupus familiaris.

Canis Lupus Familiaris Hair is classified as a Non-Standardized Animal Hair Allergenic Extract [EPC]. Related medications include Standardized Cat Hair Extract and various other non-standardized extracts like Horse Hair or Cattle Hair extracts.